Precision Diagnostics and Medicine Market to Reach $246.66 Billion by 2029
Fortune Health Study
Pioneering research on lifestyle and well-being links. Multidisciplinary approach, shaping personalized healthcare.
The global precision diagnostics and medicine market is experiencing rapid growth, with projections indicating an increase from $132.46 billion in 2023 to $246.66 billion by 2029 at an 11.1% CAGR. This expansion is fueled by the integration of AI and ML in diagnostics, increased collaborations between pharmaceutical and diagnostics companies, and the rise in direct-to-consumer testing. Companies are also investing in emerging markets by establishing manufacturing and research facilities to strengthen their global presence.
??Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215185595&utm_source=linkedin.com&utm_medium=social&utm_campaign=kk20-Pulse
North America remains the largest market due to the presence of key industry players and strong investment in biomarker-based precision therapies. Meanwhile, the Asia Pacific region is witnessing rising demand for precision diagnostics, driven by increasing chronic disease cases. However, high costs and challenges in big data integration continue to hinder widespread adoption. Despite this, advancements in AI-driven diagnostics, such as Stratipath Breast and Ataraxis Breast, are enhancing personalized treatment strategies.
Opportunities in this market are expanding beyond oncology, with a growing focus on neurodegenerative and autoimmune diseases. Collaborations, like those between NImmune Biopharma and Biotherapeutics Inc., are accelerating biomarker-based drug development. Additionally, regulatory approvals, such as Roche’s CE Mark for the VENTANA FOLR1 assay, are paving the way for more targeted therapies.
Leading companies such as Roche, Thermo Fisher Scientific, Guardant Health, and Illumina are driving innovation through strategic partnerships and technological advancements. As precision medicine continues to evolve, companies that capitalize on AI-driven diagnostics and personalized treatment approaches will gain a competitive edge in this fast-growing market.